{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:50:31Z","timestamp":1787637031248,"version":"build-2736575974"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.exer.2026.111119","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:05:08Z","timestamp":1781049908000},"page":"111119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Correcting photoreceptor diseases at their source: CRISPR strategies for cone-rod dystrophy and achromatopsia"],"prefix":"10.1016","volume":"270","author":[{"given":"Haniya Fatima","family":"Zaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamaalia","family":"Bishri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Abdul Muqtadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2286-2181","authenticated-orcid":false,"given":"Ahmed","family":"Abu-Zaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.exer.2026.111119_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/bjophthalmol-2014-306505","article-title":"The cone dysfunction syndromes","volume":"100","author":"Aboshiha","year":"2016","journal-title":"Br. J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.exer.2026.111119_bib2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/emermed-2020-209567","article-title":"Population, intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews","volume":"37","author":"Amir-Behghadami","year":"2020","journal-title":"Emerg. Med. J."},{"issue":"7","key":"10.1016\/j.exer.2026.111119_bib3","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR\u2013Cas nucleases, base editors, transposases and prime","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"10.1016\/j.exer.2026.111119_bib4","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3390\/pharmaceutics14081605","article-title":"Lentiviral vectors for ocular gene therapy","volume":"14","author":"Arsenijevic","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.exer.2026.111119_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/BTT.S429411","article-title":"Recent advancements in reducing the off-target effect of CRISPR-Cas9 genome editing","volume":"18","author":"Asmamaw","year":"2024","journal-title":"Biol. Targets & Ther."},{"issue":"3","key":"10.1016\/j.exer.2026.111119_bib6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/mt.2015.220","article-title":"In vivo CRISPR\/Cas9 gene editing corrects retinal dystrophy in the S334ter-3 rat model of autosomal dominant retinitis pigmentosa","volume":"24","author":"Bakondi","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.exer.2026.111119_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.visres.2023.108317","article-title":"Unleashing the potential of CRISPR multiplexing: harnessing Cas12 and Cas13 for precise gene modulation in eye diseases","volume":"213","author":"Bigini","year":"2023","journal-title":"Vis. Res."},{"issue":"6","key":"10.1016\/j.exer.2026.111119_bib8","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3390\/genes15060727","article-title":"Molecular mechanisms governing sight loss in inherited cone disorders","volume":"15","author":"Brotherton","year":"2024","journal-title":"Genes"},{"issue":"4","key":"10.1016\/j.exer.2026.111119_bib9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.29252\/ibj.24.4.257","volume":"24","author":"Bushehri","year":"2020","journal-title":"Iran. Biomed. J."},{"issue":"9","key":"10.1016\/j.exer.2026.111119_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/JCI158287","article-title":"CRISPR\/cas therapeutic strategies for autosomal dominant disorders","volume":"132","author":"Caruso","year":"2022","journal-title":"J. Clin. Investig."},{"issue":"16","key":"10.1016\/j.exer.2026.111119_bib11","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1093\/hmg\/ddr218","article-title":"Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy","volume":"20","author":"Carvalho","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.exer.2026.111119_bib12","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1017\/erm.2025.10","article-title":"Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects","volume":"27","author":"Cetin","year":"2025","journal-title":"Expert Rev. Mol. Med."},{"issue":"9\u201310","key":"10.1016\/j.exer.2026.111119_bib13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1089\/hum.2023.053","article-title":"CRISPR-editing therapy for Duchenne muscular dystrophy","volume":"34","author":"Chemello","year":"2023","journal-title":"Hum. Gene Ther."},{"issue":"6","key":"10.1016\/j.exer.2026.111119_bib14","doi-asserted-by":"crossref","first-page":"E517","DOI":"10.1073\/pnas.1218933110","article-title":"Human retinal gene therapy for leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement","volume":"110","author":"Cideciyan","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.exer.2026.111119_bib15","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.bbadis.2011.10.007","article-title":"Increased cone sensitivity to ABCA4 deficiency provides insight into macular vision loss in Stargardt's dystrophy","volume":"1822","author":"Conley","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.exer.2026.111119_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.652215","article-title":"Gene therapy to the retina and the cochlea","volume":"15","author":"Crane","year":"2021","journal-title":"Front. Neurosci."},{"issue":"10","key":"10.1016\/j.exer.2026.111119_bib17","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.3390\/ijms20102542","article-title":"Genome editing as a treatment for the Most prevalent causative genes of autosomal dominant retinitis pigmentosa","volume":"20","author":"Diakatou","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"11\u201312","key":"10.1016\/j.exer.2026.111119_bib18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0898-6568(00)00134-0","article-title":"Regulation of cGMP synthesis in photoreceptors: role in signal transduction and congenital diseases of the retina","volume":"12","author":"Dizhoor","year":"2000","journal-title":"Cell. Signal."},{"issue":"6213","key":"10.1016\/j.exer.2026.111119_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.exer.2026.111119_bib20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-Thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2026.111119_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2020.6418","article-title":"Analysis of pathogenic variants correctable with CRISPR base editing among patients with recessive inherited retinal degeneration","author":"Fry","year":"2021","journal-title":"JAMA Ophthalmol. [Internet]"},{"issue":"2","key":"10.1016\/j.exer.2026.111119_bib22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/biomedicines11020269","article-title":"Biology, pathobiology and gene therapy of CNG channel-related retinopathies","volume":"11","author":"Gerhardt","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.exer.2026.111119_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116636","article-title":"CRISPR-Cas9 system: a new-fangled dawn in gene editing","volume":"232","author":"Gupta","year":"2019","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.exer.2026.111119_bib24","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1038\/s41467-021-26830-7","article-title":"Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models","volume":"12","author":"Hakim","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.exer.2026.111119_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1750-1172-2-7","article-title":"Cone rod dystrophies","volume":"2","author":"Hamel","year":"2007","journal-title":"Orphanet J. Rare Dis."},{"issue":"4","key":"10.1016\/j.exer.2026.111119_bib26","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20200127","article-title":"Gene editing and CRISPR in the clinic: current and future perspectives","volume":"40","author":"Hirakawa","year":"2020","journal-title":"Biosci. Rep."},{"issue":"1","key":"10.1016\/j.exer.2026.111119_bib27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41467-017-00140-3","article-title":"Genome editing abrogates angiogenesis in vivo","volume":"8","author":"Huang","year":"2017","journal-title":"Nat. Commun."},{"issue":"1\u20132","key":"10.1016\/j.exer.2026.111119_bib28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11010-009-0331-y","article-title":"Guanylate cyclases and associated activator proteins in retinal disease","volume":"334","author":"Hunt","year":"2010","journal-title":"Mol. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.exer.2026.111119_bib29","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR\u2013Cas9 structures and mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu. Rev. Biophys."},{"issue":"10","key":"10.1016\/j.exer.2026.111119_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax1210","article-title":"CRISPR-Cas9\u2013mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of leber congenital amaurosis","volume":"5","author":"Jo","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.exer.2026.111119_bib31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.omtn.2022.03.004","article-title":"Long-term maintenance of dystrophin expression and resistance to injury of skeletal muscle in gene edited DMD mice","volume":"28","author":"Karri","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"3","key":"10.1016\/j.exer.2026.111119_bib32","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1101\/gr.219089.116","article-title":"Genome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degeneration","volume":"27","author":"Kim","year":"2017","journal-title":"Genome Res."},{"issue":"11","key":"10.1016\/j.exer.2026.111119_bib33","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1167\/iovs.08-1901","article-title":"Mutation analysis identifies GUCY2D as the major gene responsible for autosomal dominant progressive cone degeneration","volume":"49","author":"Kitiratschky","year":"2008","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2026.111119_bib34","series-title":"GeneReviews\u00ae [Internet]","article-title":"Achromatopsia","author":"Kohl","year":"1993"},{"issue":"3","key":"10.1016\/j.exer.2026.111119_bib35","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/sj.ejhg.5201269","article-title":"CNGB3 mutations account for 50% of all cases with autosomal recessive achromatopsia","volume":"13","author":"Kohl","year":"2005","journal-title":"Eur. J. Hum. Genet."},{"issue":"13","key":"10.1016\/j.exer.2026.111119_bib36","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/hmg\/ddq136","article-title":"Gene therapy rescues cone function in congenital achromatopsia","volume":"19","author":"Kom\u00e1romy","year":"2010","journal-title":"Hum. Mol. Genet."},{"issue":"10","key":"10.1016\/j.exer.2026.111119_bib37","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/cells13100800","article-title":"CRISPR-based gene therapies: from preclinical to clinical treatments","volume":"13","author":"Laurent","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.exer.2026.111119_bib40","doi-asserted-by":"crossref","first-page":"156","DOI":"10.7150\/thno.117085","article-title":"Advancements in CRISPR-Based therapies for ocular pathologies: from disease mechanisms to intervention strategies","volume":"16","author":"Li","year":"2026","journal-title":"Theranostics"},{"issue":"13","key":"10.1016\/j.exer.2026.111119_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241311200","article-title":"cGMP signaling in photoreceptor degeneration","volume":"24","author":"Li","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.exer.2026.111119_bib38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 therapeutics: progress and prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"2","key":"10.1016\/j.exer.2026.111119_bib41","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41551-020-00656-y","article-title":"Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice","volume":"5","author":"Ling","year":"2021","journal-title":"Nat. Biomed. Eng."},{"issue":"2","key":"10.1016\/j.exer.2026.111119_bib42","first-page":"153","article-title":"Delivery strategies for CRISPR\/cas genome editing tool for retinal dystrophies: challenges and opportunities","volume":"17","author":"Lohia","year":"2022","journal-title":"Asian J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.exer.2026.111119_bib43","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","article-title":"Development of a gene-editing approach to restore vision loss in leber congenital amaurosis type 10","volume":"25","author":"Maeder","year":"2019","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.exer.2026.111119_bib44","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1089\/hum.2018.193","article-title":"Somatic gene editing of GUCY2D by AAV-CRISPR\/Cas9 alters retinal structure and function in mouse and macaque","volume":"30","author":"McCullough","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.exer.2026.111119_bib45","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.omtm.2023.05.020","article-title":"Development of an AAV-CRISPR-Cas9-based treatment for dominant cone-rod dystrophy 6","volume":"30","author":"Mellen","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"8","key":"10.1016\/j.exer.2026.111119_bib46","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/j.semperi.2018.09.003","article-title":"CRISPR\/Cas9 gene-editing: research technologies, clinical applications and ethical considerations","volume":"42","author":"Memi","year":"2018","journal-title":"Semin. Perinatol."},{"issue":"3","key":"10.1016\/j.exer.2026.111119_bib47","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.survophthal.2006.02.007","article-title":"Progressive cone and cone-rod dystrophies: phenotypes and underlying molecular genetic basis","volume":"51","author":"Michaelides","year":"2006","journal-title":"Surv. Ophthalmol."},{"issue":"1","key":"10.1016\/j.exer.2026.111119_bib48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40291-021-00565-z","article-title":"Achromatopsia: genetics and gene therapy","volume":"26","author":"Michalakis","year":"2022","journal-title":"Mol. Diagn. Ther."},{"issue":"2","key":"10.1016\/j.exer.2026.111119_bib49","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.molcel.2021.12.026","article-title":"CRISPR-based genome editing through the lens of DNA repair","volume":"82","author":"Nambiar","year":"2022","journal-title":"Mol. Cell"},{"issue":"2","key":"10.1016\/j.exer.2026.111119_bib50","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11095-018-2564-5","article-title":"Adeno-associated viral gene therapy for inherited retinal disease","volume":"36","author":"Ong","year":"2019","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.exer.2026.111119_bib51","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014A web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.exer.2026.111119_bib52","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.exer.2026.111119_bib53","series-title":"Retinal Degenerative Diseases [Internet]","first-page":"639","article-title":"Achromatopsia as a potential candidate for gene therapy","author":"Pang","year":"2010"},{"issue":"4","key":"10.1016\/j.exer.2026.111119_bib54","first-page":"533","article-title":"The application of CRISPR\/Cas9 for the treatment of retinal diseases","volume":"90","author":"Peddle","year":"2017","journal-title":"Yale J. Biol. Med."},{"issue":"52","key":"10.1016\/j.exer.2026.111119_bib55","doi-asserted-by":"crossref","first-page":"18301","DOI":"10.1074\/jbc.RA120.015553","article-title":"GUCY2D mutations in retinal guanylyl cyclase 1 provide biochemical reasons for dominant cone-rod dystrophy but not for stationary night blindness","volume":"295","author":"Peshenko","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.exer.2026.111119_bib56","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13287-024-03804-2","article-title":"Clinical exome analysis and targeted gene repair of the c.1354dupT variant in iPSC lines from patients with PROM1-related retinopathies exhibiting diverse phenotypes","volume":"15","author":"Puertas-Neyra","year":"2024","journal-title":"Stem Cell Res. Ther."},{"issue":"2","key":"10.1016\/j.exer.2026.111119_bib57","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymthe.2016.12.006","article-title":"CRISPR\/Cas9-Mediated genome editing as a therapeutic approach for leber congenital amaurosis 10","volume":"25","author":"Ruan","year":"2017","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.exer.2026.111119_bib58","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1523\/JNEUROSCI.2985-17.2018","article-title":"GUCY2D cone\u2013rod Dystrophy-6 is a \u201cPhototransduction Disease\u201d triggered by abnormal calcium feedback on retinal membrane guanylyl cyclase 1","volume":"38","author":"Sato","year":"2018","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.exer.2026.111119_bib59","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.3390\/ijms24043655","article-title":"High-efficiency CRISPR\/Cas9-Mediated correction of a homozygous mutation in achromatopsia-patient-derived iPSCs","volume":"24","author":"Siles","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.exer.2026.111119_bib60","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.trsl.2013.01.001","article-title":"Pluripotent stem cells and gene therapy","volume":"161","author":"Simara","year":"2013","journal-title":"Transl. Res."},{"issue":"7631","key":"10.1016\/j.exer.2026.111119_bib61","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nature20565","article-title":"In vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration","volume":"540","author":"Suzuki","year":"2016","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.exer.2026.111119_bib62","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.1167\/iovs.10-5680","article-title":"Progressive loss of cones in achromatopsia: an imaging study using spectral-domain optical coherence tomography","volume":"51","author":"Thiadens","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"9","key":"10.1016\/j.exer.2026.111119_bib63","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.ophtha.2018.04.001","article-title":"Clustered regularly interspaced short palindromic repeats-based genome surgery for the treatment of autosomal dominant retinitis pigmentosa","volume":"125","author":"Tsai","year":"2018","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.exer.2026.111119_bib64","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.exer.2026.111119_bib65","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1086\/323613","article-title":"CNGA3 mutations in hereditary cone photoreceptor disorders","volume":"69","author":"Wissinger","year":"2001","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.exer.2026.111119_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.oret.2017.09.015","article-title":"Genome editing in retinal diseases using CRISPR technology","volume":"2","author":"Yiu","year":"2018","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"10.1016\/j.exer.2026.111119_bib67","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14716","article-title":"Nrl knockdown by AAV-delivered CRISPR\/Cas9 prevents retinal degeneration in mice","volume":"8","author":"Yu","year":"2017","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.exer.2026.111119_bib68","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/cr.2017.57","article-title":"Gene and mutation independent therapy via CRISPR-Cas9 mediated cellular reprogramming in rod photoreceptors","volume":"27","author":"Zhu","year":"2017","journal-title":"Cell Res."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483526002757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483526002757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:39:26Z","timestamp":1784295566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483526002757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":68,"alternative-id":["S0014483526002757"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2026.111119","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correcting photoreceptor diseases at their source: CRISPR strategies for cone-rod dystrophy and achromatopsia","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2026.111119","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111119"}}